I’d agree with you FP.
Should HER-Vaxx be the least exciting then it augers well for the rest of the pipeline. The immune response was found to be even greater when combined with Herceptin, therefore you’d expect that it would naturally become a combination therapy in that already huge market if you can avoid side effects. Add in those with gastric cancer and it further increases its value. Now for those more exciting lines of research.
The trials are starting later than we expected, however that has given more time to advance these other lines of research and hit the market with multiple targets around the same time. I like the idea.
Here’s hoping for successful trials and a big thankyou to all those who participate. My best wishes to you.
I’d agree with you FP. Should HER-Vaxx be the least exciting...
-
- There are more pages in this discussion • 32 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
4.8¢ |
Change
0.002(4.35%) |
Mkt cap ! $357.0M | |||
| Open | High | Low | Value | Volume |
| 4.7¢ | 4.9¢ | 4.6¢ | $977.7K | 20.56M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 13 | 3232340 | 4.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 4.8¢ | 854027 | 4 |
View Market Depth
| Last trade - 16.10pm 11/11/2024 (20 minute delay) ? |
| IMU (ASX) Chart |